摘要
背景与目的:已知肿瘤细胞生长所需能量是通过葡萄糖转运体蛋白1(glucose transporter protein1,GLUT-1)完成的葡萄糖代谢来提供的。另外,参与基因损伤修复的催化亚单位——DNA蛋白激酶(DNA-dependent protein kinase catalytic subunit,DNA-PKcs)在肿瘤形成中也起着非常重要的作用。本研究旨在探讨GLUT-1和DNA-PKcs在卵巢浆液性肿瘤组织中的表达及其与肿瘤生物学行为的关系和意义。方法:免疫组化方法检测80例卵巢浆液性肿瘤组织中GLUT-1、DNA-PKcs的表达,分析其异常表达与临床病理参数之间的相关性,以正常卵巢组织20例为对照。结果:正常卵巢组织GLUT-1表达全阴性,DNA-PKcs表达全阳性。GLUT-1在良性、交界性、恶性卵巢浆液性肿瘤中的表达呈增高的趋势,与卵巢浆液性肿瘤的发生发展呈正相关(rs=0.943,P<0.01);
BACKGROUND ＆ OBJECTIVE： Cancer cell growth is supported by glucose metabolism of glucose transporter protein 1 （GLUT-1）. In addition, the participation of DNA-dependent protein kinase catalytic subunit （DNA-PKcs） in genome damage-repairing is important for oncogenesis prevention. This study was to evaluate the expression and biologic significance of GLUT-1 and DNA-PKcs in serous ovarian tumors. METHODS： The expression of GLUT-1 and DNA-PKcs in 20 specimens of normal ovarian tissues, 20 specimens of serous cystadenoma, 20 specimens of borderline serous cystadenoma, and 40 specimens of serous cystadenocarcinoma were detected by SP immunohistochemistry. The correlation of GLUT-1 and DNA-Pkcs expression to clinicopathologic characteristics of serous ovarian tumors was analyzed by Chi-square test. RESULTS： The positive rate of GLUT-1 was significantly higher in malignant and borderline serous ovarian carcinomas than in benign tumors and normal ovarian tissues （100% and 55% vs. 0% and 0%, P〈0.01 ）. The differences in the positive rate of DNA-PKcs were signifinant among normal ovarian tissues, benign, borderline, and malignant serous ovarian tumors （100%, 95%, 90%, and 60%, P〈0.01）. GLUT-1 experssion was negatively correlated to DNA-PKcs expression （rs=-0.270, P〈0.01）. GLUT-1 expression in borderline and malignant serous ovarian tumors was related to intraperitoneal implants, ascites, lymph node metastasis, and FIGO stage, but DNA-PKcs was only related to FIGO stage and lymph node metastasis （P〈0.05）. CONCLUSION： The expression of GLUT-1 and the loss of DNA- PKcs may be closely related to the malignant transformation of serous ovarian tumors.
出处
《癌症》
SCIE
CAS
CSCD
北大核心
2007年第11期1188-1193,共6页
Chinese Journal of Cancer
